Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo

Raltegravir, an inhibitor of human immunodeficiency virus-1 (HIV-1) integrase, has been used to treat HIV/acquired immunodeficiency syndrome; however, its therapeutic effects on pulmonary fibrosis have not been investigated. In this study, the in vitro effects of raltegravir (RAV) on transforming gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xue, Huang, Haidi, Zhang, Guanghua, Li, Defang, Wang, Hongbo, Jiang, Wanglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710384/
https://www.ncbi.nlm.nih.gov/pubmed/31481891
http://dx.doi.org/10.3389/fphar.2019.00903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710384/
https://www.ncbi.nlm.nih.gov/pubmed/31481891
http://dx.doi.org/10.3389/fphar.2019.00903

Ejemplares similares